Henry Haley, MD
Ophthalmology · Metairie, LANPI 1972578516
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,890 of the $6,621 with a category attached, or 73.9%. 17 manufacturers reported payments, led by Medical Device Business Services, Inc. at 27.8% of the total. Reporting peaked in 2024 at $3,081 and has fallen 77.0% since, to $707 in 2025.
Across 125 payments — averaging $52.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Alcon$1K
- Glaukos Corporation$1K
- Rxsight Inc$468
- AbbVie$349
- plus $416 from 11 others
Across 9 payments — averaging $5555.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$50K
What the payments were for
- Consulting fees$5008%
- Speaking & faculty fees$260%
- Travel & lodging$1,14017%
- Food & beverage$4,89074%
- Gifts$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 10 | $1,838 |
| Johnson & Johnson Surgical Vision, Inc. | 34 | $1,326 |
| Alcon | 36 | $1,217 |
| Glaukos Corporation | 5 | $1,006 |
| Rxsight Inc | 9 | $468 |
| AbbVie(2 entities) | 15 | $349 |
| Beaver-visitec International, Inc. | 2 | $117 |
| Sun Pharmaceutical Industries Inc. | 3 | $86 |
| Johnson & Johnson | 1 | $38 |
| Kala Pharmaceuticals, Inc. | 2 | $36 |
| Dompe US, Inc. | 1 | $33 |
| NEW World Medical,inc. | 2 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec USA, Inc. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
| Eyepoint US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIS$1,571
- Tecnis IOL$619
- Tecnis Simplicity$393
- VERITAS Vision System$268
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$240
- iDoseTR$200
- iDose$186
- CATALYS SYSTEM$150
- AcrySof IQ PanOptix$138
- ReSTOR$126
- RXSIGHT CONTACT LENS$113
- RXSIGHT INJECTOR HANDPIECE$113
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$113
- RXSIGHT INJECTOR CARTRIDGE$113
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$113
How this compares
$6,621 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 1,095 | $64,865 |
| Ketorolac Tromethamine | 1,166 | $37,083 |
| Cyclosporine | 22 | $13,946 |
| MoxifloxacinMoxifloxacin Hcl | 556 | $11,362 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $10,021 |
| Ofloxacin | 764 | $9,953 |
| LumiganBimatoprost | 12 | $4,213 |
| Latanoprost | 223 | $1,777 |
| Dexamethasone Sodium Phosphate | 42 | $1,749 |
| Brimonidine Tartrate | 46 | $1,548 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,357 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 83 | $1,118 |
| Timolol Maleate | 59 | $596 |
| Diclofenac Sodium | 36 | $459 |
| Dorzolamide Hcl | 14 | $249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan | $349 | $14,23445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Metairie
- Ethan SternMetairie$16K
- John FrisbeeMetairie$14K
- Benjamin GuidryMetairie$9K
- Scott LanouxMetairie$8K
- Tyler GoffMetairie$7K
- John BoyleMetairie$7K
- Nicholas FrisardMetairie$7K
- Brandon DavisMetairie$7K
- Owen LacourMetairie$6K
- Joshua GroetschMetairie$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.